AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get moving
Target
Upside 224%
Price (€) 3.11
Market Cap (€M) 108
Perf. 1W: 12.0%
Perf. 1M: -8.48%
Perf. 3M: 0.16%
Perf Ytd: 9.83%
10 day relative perf. to stoxx600: 2.00%
20 day relative perf. to stoxx600: -0.21%
EPS change05/09/2022

Adjusting our forecasts to the new number of shares

Change in EPS2022 : € -0.23 vs -0.26ns
2023 : € -0.25 vs -0.31ns

We have adjusted our numbers to the current number of shares (after the latest exercise of subscription rights) which now stands at 34.83m as of August 2022. As a result, the loss per share for FY22/23 decreases.



Change in NAV€ 12.3 vs 13.3-7.88%

We have adjusted our numbers to the current number of shares (after the exercise of subscription rights) which now stands at 34.83m as of August 2022.



Change in DCF€ 13.3 vs 14.6-9.05%

We have adjusted our numbers to the current number of shares (after the latest exercise of subscription rights) which now stands at 34.83m as of August 2022.



Updates

26 Sep 22 EPS change
Minor changes after H1 22

23 Sep 22 Earnings/sales releases
A rather reassuring H1 22

29 Mar 22 Earnings/sales releases
FY21: not very meaningful, as expected

17 Dec 21 Financing issue
New financing

24 Sep 21 Earnings/sales releases
H1 21: unsurprising (as usual)

.